PCS-CM190-100μg / 询价
PCS-CM190-500μg / 询价
PCS-CM190-500μgx2 / 询价
表达区间及表达系统(Source)
|
Recombinant Cynomolgus PCSK9 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Glu151-Gln811 [Accession | A0A2K5TZC4]. |
分子量大小(Molecular Weight)
|
Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-70 kDa (pro-form) and 15-20 kDa (mature form) based on Bis-Tris PAGE result. |
纯度(Purity)
|
> 95% as determined by Bis-Tris PAGE |
内毒素(Endotoxin)
|
Less than 1EU per μg by the LAL method. |
制剂(Formulation)
|
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
重构方法(Reconstitution)
|
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
存储(Storage)
|
-20 to -80°C for 12 months as supplied from date of receipt. |
Recombinant Cynomolgus PCSK9 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Glu151-Gln811 [Accession | A0A2K5TZC4].
Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-70 kDa (pro-form) and 15-20 kDa (mature form) based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
PCSK9
(1)McKenney, James M. Understanding PCSK9 and anti-PCSK9 therapies[J]. Journal of Clinical Lipidology, 2015, 9(2):170-186.
PCS-CM190-100μg / 询价
PCS-CM190-500μg / 询价
PCS-CM190-500μgx2 / 询价
货号* | 规格* | 名称 | 数量* | |
---|---|---|---|---|
货号* | 名称 | 批号* | |
---|---|---|---|